Pharmaceutical Preparations · DE · CIK 1868279
ArriVent BioPharma develops and commercializes differentiated medicines for unmet cancer needs, focusing on firmonertinib and novel therapeutics
Comparable business profile · signals at a glance
In the 90 days to Dec 10, 2025: 1 sold $13.0M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 10, 2025 | Hhlr Advisors, Ltd.TenPercentOwner | Sell | 555,555 | $23.37 | $13.0M |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.